Older people are disproportionately affected by the COVID-19 pandemic, which has had a
profound impact on research as well as clinical service delivery. This commentary identifies …

In this study, we quantify the severity of drug-induced dyskinesias in the arms of Parkinson's
disease (PD) patients using digitised spiral-drawing tasks. Two spiral drawings, namely a …

Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial
morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 …

Many now believe the holy grail for the next stage of therapeutic advance surrounds the
development of disease-modifying approaches aimed at intercepting the year-on-year …

Introduction There is an ongoing digital revolution in the field of Parkinson's disease (PD)
for the objective measurement of motor aspects, to be used in clinical trials and possibly …

Background Up to half of patients with dementia may not receive a formal diagnosis, limiting
access to appropriate services. It is hypothesised that it may be possible to identify …

Objective To provide guidance to researchers, funders, regulators and study delivery teams
to ensure that research on COVID-19 is inclusive, particularly of groups disproportionately …

Proliferator-activated receptor γ (PPARγ) activation can result in transcription of proteins
involved in oxidative stress defence and mitochondrial biogenesis which could rescue …

Introduction Parkinson’s disease (PD) is a progressive neurodegenerative condition
affecting approximately 185,000 people in the UK. No drug has been proven to slow disease …

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use
in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a …